Investor News

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Company News, Investor News /

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix […]

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays Read More »

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director

Company News, Investor News /

Appointment brings in-depth expertise of company development and investment and enhanced contacts in Asia to Oxford Vacmedix Press Release – Appointment of Mr Choon-Yoon Lim as Director Oxford 19th October 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mr. Chong-Yoon Lim as a

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director Read More »